UPDATE: Abbott (ABT) Tops Q3 EPS by 1c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Abbott Labs (ABT) PT Raised to $65 at Jefferies
October 19, 2017 9:25 AM EDTJefferies raised its price target on Abbott Labs (NYSE: ABT) to $65.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. Org growth in 3Q of +5.6% was the best in 2 years and largely validates the recent portfolio moves. Driving the performance... More
Abbott Labs (ABT) PT Raised to $60 at Morgan Stanley
October 19, 2017 8:54 AM EDTMorgan Stanley raised its price target on Abbott Labs (NYSE: ABT) to $60.00 (from $53.00) while maintaining a Equalweight rating.
... MoreAbbott Labs (ABT) PT Raised to $63 at Stifel Following 3Q Release
October 18, 2017 5:06 PM EDTStifel raised its price target on Abbott Labs (NYSE: ABT) to $63.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. The company reported above-expectation 5.6% comparable operational sales growth and above-consensus EPS at $0.66 (vs. $0.65 Consensus). positive 3Q highlights included: key product approvals, improving pipeline... More
